Aytu BioPharma logo

Aytu BioPharmaNASDAQ: AYTU

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 September 2008

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$11.74 M
-83%vs. 3y high
19%vs. sector
-vs. 3y high
-vs. sector
-35%vs. 3y high
26%vs. sector
-85%vs. 3y high
5%vs. sector

Price

regular market | Mon, 04 Nov 2024 14:30:00 GMT
$1.91-$0.03(-1.55%)

Dividend

No data over the past 3 years
$17.98 M$13.77 M
$17.98 M-$4.62 M

Analysts recommendations

Institutional Ownership

AYTU Latest News

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
https://www.accesswire.com/viewarticle.aspx?id=930516&lang=en14 October 2024 Sentiment: POSITIVE

DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time.

Aytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call Transcript
seekingalpha.com26 September 2024 Sentiment: NEUTRAL

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2024 Results Conference Call September 26, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings, welcome to the Aytu BioPharma's Fiscal 2024 Q4 Earnings Call. At this time, all participants have been placed on a listen-only mode.

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
accesswire.com26 September 2024 Sentiment: POSITIVE

Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023 $20.0 million cash balance at June 30, 2024 Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levels Company to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2024 full year and fourth quarter.

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
accesswire.com19 September 2024 Sentiment: POSITIVE

DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter, after the market close on Thursday, September 26, 2024. The Company has scheduled a conference call and webcast that same day, Thursday, September 26, 2024, at 4:30 p.m.

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
accesswire.com08 August 2024 Sentiment: POSITIVE

DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024. Webcast The webcasted fireside chat will take place at 12:15 p.m.

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
accesswire.com06 August 2024 Sentiment: POSITIVE

Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx Segment Eliminates Materially All Remaining Expenses Associated with the Consumer Health Business Provides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / ACCESSWIRE / August 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that following the wind down of operations, it has entered into a definitive agreement to divest its Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for Aytu to receive revenue-based royalty payments on future sales of former Consumer Health business products.

Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
Seeking Alpha14 February 2024 Sentiment: POSITIVE

Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
Seeking Alpha14 November 2023 Sentiment: POSITIVE

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Robert Blum Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023. Joining us on today's call is Aytu's CEO, Josh Disbrow, and the company's Chief Financial Officer, Mark Oki.

Best Penny Stocks? 4 Hot Stocks With News This Week
PennyStocks28 September 2023 Sentiment: POSITIVE

What do you consider the best penny stocks? Are they the ones exploding higher within a single session?

Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript
Seeking Alpha27 September 2023 Sentiment: POSITIVE

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2023 Earnings Call Transcript September 27, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call.

What type of business is Aytu BioPharma?

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

What sector is Aytu BioPharma in?

Aytu BioPharma is in the Healthcare sector

What industry is Aytu BioPharma in?

Aytu BioPharma is in the Drug Manufacturers - Specialty & Generic industry

What country is Aytu BioPharma from?

Aytu BioPharma is headquartered in United States

When did Aytu BioPharma go public?

Aytu BioPharma initial public offering (IPO) was on 25 September 2008

What is Aytu BioPharma website?

https://aytubio.com

Is Aytu BioPharma in the S&P 500?

No, Aytu BioPharma is not included in the S&P 500 index

Is Aytu BioPharma in the NASDAQ 100?

No, Aytu BioPharma is not included in the NASDAQ 100 index

Is Aytu BioPharma in the Dow Jones?

No, Aytu BioPharma is not included in the Dow Jones index

When was Aytu BioPharma the previous earnings report?

No data

When does Aytu BioPharma earnings report?

The next expected earnings date for Aytu BioPharma is 29 November 2024